Please assess the completion status of the following clinical trial:

Trial Title: Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have suspicion of DCIS or early invasive breast cancer on mammography.~* Patients must have histologically confirmed diagnosis of DCIS or early invasive breast cancer on core biopsy for final registration.~* Patients must be over 18 years of age~* Patients must be postmenopausal as defined by one of the following criteria:~  1. Prior bilateral oophorectomy OR~ 2. \> 12 months since LMP with no prior hysterectomy OR~ 3. a \& b not applicable AND age \>=50~* Patients must be positive for either ER or PR or both~* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Patients must not have diagnosis of osteoporosis (T-score -2.5 according to the WHO)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anastrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).